Pregnancy and Tumor Outcomes in Women with Prolactinoma

Abstract

Context Management of prolactinomas during pregnancy has always been a challenge. There is a concern about the risk of tumor growth, as well as the effects of the treatment on the developing fetus. Another issue that has been less studied is the outcome of women with prolactinoma after pregnancy and lactation.

Objectives To evaluate remission of hyperprolactinaemia after pregnancy and lactation in women with prolactinoma. To describe the safety of dopamine agonists for the fetus and pregnancy outcomes.

Methods A retrospective study of 32 pregnancies in women with prolactinoma was conducted in a single-centre. Other causes of hyperprolactinemia were excluded. Prolactin level was recorded at the time of diagnosis, during treatment, and during follow-up.

Results The pregnancies resulted in one spontaneous abortion (3.1%) and 31 live births (96.9%). No stillbirths, multiple or ectopic pregnancies or trophoblastic disease were recorded. There was only one malformation (club foot) recorded (3.1%) and normalisation of prolactin after pregnancy without medical treatment occurred in 12% of patients.

Conclusions Fetal exposure to bromocriptine or cabergoline during pregnancy is not associated with an increased risk of adverse neonatal or pregnancy disclosures. There is considerable diversity among endocrinologists in the management of prolactinomas during pregnancy and after birth, which indicates that there is a need for better consensus and for carefully drawn-up guidelines to follow.

Key words

prolactin - pituitary tumor - hyperprolactinemia - dopamine agonists

• References

• 1 Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005; 8: 3-6
• 2 Daly AF, Rixhon M, Adam C. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775
• 3 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
• 4 Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 2015; 172: R205-R213
• 5 Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25: 885-896
• 6 Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine 2014; 47: 64-69
• 7 Domingue ME, Devuyst F, Alexopoulou O. et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 2014; 80: 642-648
• 8 Rjosk HK, Fahlbusch R, von Werder K. Influence of pregnancies on prolactinomas. Acta endocrinologica 1982; 100: 337-346
• 9 Crosignani PG, Mattei AM, Severini V. et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 1992; 44: 175-180
• 10 Jeffcoate WJ, Pound N, Sturrock ND. et al. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996; 45: 299-303
• 11 Raymond JP, Goldstein E, Konopka P. et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res 1985; 22: 239-246
• 12 Randeva HS, Davis M, Prelevic GM. Prolactinoma and pregnancy. Br J Obstet Gynaecol 2000; 107: 1064-1068
• 13 Bronstein MD. Prolactinomas and pregnancy. Pituitary 2005; 8: 31-38
• 14 Molitch ME. Pituitary tumors and pregnancy. Growth Horm IGF Res 2003; 13: S38-S44
• 15 Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25: 885-896
• 16 Hamilton BE, Martin JA, Osterman MJ. et al. Final Data for 2014. Natl Vital Stat Rep 2015; 64: 1-64
• 17 Auriemma RS, Perone Y, Di Sarno A. et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 2013; 98: 372-379
• 18 Casanueva FF, Molitch ME, Schlechte JA. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 265-273
• 19 Ikegami H, Aono T, Koizumi K. et al. Relationship between the methods of treatment for prolactinomas and the puerperal lactation. Fertil Steril 1987; 47: 867-869
• 20 Colao A, Abs R, Barcena DG. et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008; 68: 66-71
• 21 Ricci E, Parazzini F, Motta T. et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16: 791-793
• 22 Robert E, Musatti L, Piscitelli G. et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333-337
• 23 Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823-827
• 24 Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry 2001; 71: 542-545
• 25 Witek P, Zielinski G, Maksymowicz M. et al. Transsphenoidal surgery for a life-threatening prolactinoma apoplexy during pregnancy. Neuro Endocrinol Lett 2012; 33: 483-488
• 26 Rajasekaran S, Vanderpump M, Baldeweg S. et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) 2011; 74: 9-20
• 27 Brodsky JB, Cohen EN, Brown Jr BW. et al. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980; 138: 1165-1167
• 28 Tyson JE, Hwang P, Guyda H. et al. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113: 14-20
• 29 Serri O, Chik CL, Ur E. et al. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169: 575-581
• 30 Almalki MH, Ur E, Johnson M. et al. Management of prolactinomas during pregnancy – a survey of four Canadian provinces. Clin Invest Med 2012; 35: E96-104
• 31 Beshyah SA, Sherif IH, Chentli F. et al. Management of prolactinomas: a survey of physicians from the Middle East and North Africa. Pituitary 2016; 1-10
• 32 Vilar L, Naves LA, Casulari LA. et al. Management of prolactinomas in Brazil: an electronic survey. Pituitary 2010; 13: 199-206